Development and Validation of an Early Prediction Model for Severe Mycoplasma Pneumoniae Pneumonia in Children
NCT ID: NCT07333833
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
964 participants
OBSERVATIONAL
2018-01-01
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children
NCT07064278
Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia
NCT03996967
Treatment of Mycobacterium Xenopi Pulmonary Infection
NCT01298336
Supportive Treatment and Antibiotics for Mild Pediatric Pneumonia
NCT05726253
Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Children CAP
NCT02668237
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Development
A primary cohort of eligible patients from the Beijing Friendship Hospital between 2018-1-1 and 2024-5-31 is used for model derivation.
medical history taking, blood test, pulmonary ultrasound
medical history taking, blood test, pulmonary ultrasound are used for MPP and SMPP diagnosis
Internal cross-validation
A cohort of consecutive patients from the Beijing Friendship Hospital between 2018-1-1 and 2024-5-31 is used for internal cross-validation.
medical history taking, blood test, pulmonary ultrasound
medical history taking, blood test, pulmonary ultrasound are used for MPP and SMPP diagnosis
External validation
A cohort of patients from the Beijing Friendship Hospital between 2024-6-1 and 2025-6-30 is used for internal cross-validation.
medical history taking, blood test, pulmonary ultrasound
medical history taking, blood test, pulmonary ultrasound are used for MPP and SMPP diagnosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
medical history taking, blood test, pulmonary ultrasound
medical history taking, blood test, pulmonary ultrasound are used for MPP and SMPP diagnosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with Mycoplasma pneumoniae pneumonia
* hospital stay ≥ 72 hours
Exclusion Criteria
* cardiovascular conditions
* inherited metabolic disorders
* immuno-deficiency disorders
* coinfection with pathogens other than Mycoplasma pneumoniae
1 Month
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Friendship Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
V120250926
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.